Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Deals Drug

AusperBio and Asymchem Form Strategic Partnership for Drug Development

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Bulletin Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

Fineline Cube Mar 10, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...

Company Deals

HuiLiao Biomedical Raises RMB 100 Million in Pre-Series A Round for mRNA Development

Fineline Cube Mar 10, 2023

China-based nucleic acid drug specialist Suzhou HuiLiao Biomedical Technology Co., Ltd has reportedly raised over...

Company Drug

InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China

Fineline Cube Mar 10, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...

Company Deals

Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Therapies

Fineline Cube Mar 10, 2023

China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million)...

Company Deals

Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development

Fineline Cube Mar 10, 2023

Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions”...

Company Medical Device

Lifetech Scientific’s IBS Angel Stent Receives CE MDR Certification in EU

Fineline Cube Mar 10, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received CE MDR certification...

Company Deals

Olipharma Raises Funds in Pre-Series A+ Round to Expand Manufacturing Facilities

Fineline Cube Mar 10, 2023

Olipharma, a small nucleic acid drug Contract Development and Manufacturing Organization (CDMO) based in Suzhou,...

Company Drug

Inventiva and Chia Tai Tianqing File Clinical Trial for Lanifibranor with CDE

Fineline Cube Mar 10, 2023

France-based Inventiva S.A. and China’s Chia Tai Tianqing have filed a clinical trial application with...

Company Drug

Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors

Fineline Cube Mar 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...

Company Deals

AusperBio and Asymchem Form Strategic Partnership for New Drug R&D and Services

Fineline Cube Mar 10, 2023

China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...

Policy / Regulatory

NHSA’s 2022 Healthcare Security Report Reveals Break-Even Performance

Fineline Cube Mar 10, 2023

The National Healthcare Security Administration (NHSA) has released its annual “Healthcare Security Development Statistical Bulletin”...

Company Drug

Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008

Fineline Cube Mar 10, 2023

China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...

Company Drug

Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma

Fineline Cube Mar 10, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...

Company Deals

HealiRNA Secures RMB 100 Million in Pre-Series A Funding for Nucleic Acid Drug Development

Fineline Cube Mar 10, 2023

China-based nucleic acid drug specialist Suzhou HealiRNA has reportedly raised over RMB 100 million (USD...

Company Drug

InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China

Fineline Cube Mar 10, 2023

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...

Company Deals

Thederma Pharmaceuticals Raises RMB 100 Million for AhR-Targeted Autoimmune Therapies

Fineline Cube Mar 10, 2023

China-based Shanghai Thederma Pharmaceuticals Co., Ltd has reportedly raised RMB 100 million (USD 14.35 million)...

Company Deals

Xinrui Medtech Secures Pre-Series A Funding for Cardiovascular Device Development

Fineline Cube Mar 10, 2023

Xinrui Medtech, a cardiovascular device maker based in Suzhou, has reportedly raised “tens of millions”...

Posts pagination

1 … 547 548 549 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.